Shandong Sanyuan Biotechnology ,Ltd. EBIT

Shandong Sanyuan Biotechnology ,Ltd. (301206.SZ) currently reports a EBIT of $46M as of September 2026. That compares with $120M in the prior-year period — down 63.2% year over year. That is below the sector sector average of $2.6T. Use the charts on this page to explore Shandong Sanyuan Biotechnology ,Ltd.'s EBIT history and peer comparisons.

Shandong Sanyuan Biotechnology ,Ltd.'s EBIT decreased from $120M to $46M — a 63.2% year-over-year decrease (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Shandong Sanyuan Biotechnology ,Ltd.'s EBIT of $46M is lower than the its sector sector average of $2.6T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Shandong Sanyuan Biotechnology ,Ltd. reported $46M in EBIT as of September 2026. That compares with $120M in the prior-year period — down 63.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $46M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $2.6T. From there, open related valuation or income-statement pages for Shandong Sanyuan Biotechnology ,Ltd., and consider following 301206.SZ for alerts when major investors trade the stock.